**Asthma pill could reduce symptoms in severe sufferers**

Posted by [**ap507**](https://www2.le.ac.uk/author/ap507) at Aug 05, 2016 11:31 PM | [**Permalink**](https://www2.le.ac.uk/offices/press/press-releases/2016/august/asthma-pill-could-reduce-symptoms-in-severe-sufferers)

**Issued by the University of Leicester Press Office on 5 August**

**“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester**

**An audio interview with Professor Chris Brightling about the research and images are available here:<https://www.dropbox.com/sh/02pxh4awi5di10s/AAAwqaU8pEnSDpNtqhkdk2B1a?dl=0>**

University of Leicester researcher in potential medical breakthrough

The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.

The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”

Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.

Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.

The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.

A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.

The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.

The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.

People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.

The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.

Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.

Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.

“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.

“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.

“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”

Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.

The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.

“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”

After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.

Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.

Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.

Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.

The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals - focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).

AirPROM stands for ‘Airway Disease Predicting Outcomes through Patient Specific Computational Modelling’.

This is the technical name for the five year Europe-wide, EU funded project, which aimed to produce computer and physical models of the whole human airway system for people with asthma and chronic obstructive pulmonary disease (COPD).

AirPROM has demonstrated how an integrated approach, involving modelling, measurement and clinical validation, can accelerate the development of new therapies and improve existing methods.

AirPROM is led by the University of Leicester and coordinated by Professor Brightling.

**If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts:**[**http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract**](http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract)

**ENDS**

**Contact information:**

* For further details or to arrange an interview with the professor or the case study please email [**oliver.jelley@ojpr.co.uk**](mailto:oliver.jelley@ojpr.co.uk) or[**Fiona.bailey@ojpr.co.uk**](mailto:Fiona.bailey@ojpr.co.uk)

**Notes to editors:**

* The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit[**http://www.nihr.ac.uk**](http://www.nihr.ac.uk/).
* The NIHR Leicester Respiratory Biomedical Research Unit based at Glenfield Hospital is a partnership between University of Leicester and University Hospitals of Leicester NHS Trust.  In 2012 the respiratory research department became part of a multi-million pound government investment by the NIHR, to become one of only twenty BRUs within England. The Unit will focus on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).  The funding has allowed the development of a specially designed unit including clinical space and specialist team allowing first class investigations into lung disease  [**http://www.leicsrespiratorybru.nihr.ac.uk/**](http://www.leicsrespiratorybru.nihr.ac.uk/)